vtv
therapeutics
announces
appointment
edward
taibi
board
directors
high
point
globe
newswire
vtv
therapeutics
nasdaq
vtvt
announced
appointment
edward
taibi
executive
vice
president
macandrews
forbes
incorporated
macandrews
vtv
board
directors
effective
august
taibi
serve
term
date
next
annual
meeting
company
stockholders
ed
add
significant
value
vtv
board
member
tremendous
asset
helping
drive
goals
said
steve
holcombe
ceo
vtv
therapeutics
member
senior
leadership
team
macandrews
look
forward
leveraging
keen
insights
future
taibi
gained
extensive
business
leadership
experience
course
tenure
macandrews
advising
transformative
business
development
opportunities
well
large
complex
capital
markets
financing
transactions
prior
joining
macandrews
taibi
served
lawyer
mergers
acquisitions
group
skadden
arps
slate
meagher
flom
llp
honored
join
vtv
therapeutics
board
directors
said
edward
taibi
look
forward
collaborating
vtv
management
team
progress
development
company
pipeline
innovative
clinical
drug
candidates
potential
significantly
improve
lives
patients
suffering
type
diabetes
alzheimer
macandrews
holding
company
portfolio
public
private
companies
diverse
industries
macandrews
significant
investor
vtv
predecessor
companies
years
vtv
therapeutics
vtv
therapeutics
biopharmaceutical
company
focused
developing
oral
small
molecule
drug
candidates
vtv
pipeline
clinical
drug
candidates
led
programs
adjunctive
treatment
type
diabetes
alzheimer
disease
inflammatory
disorders
vtv
development
partners
pursuing
additional
indications
type
diabetes
chronic
obstructive
pulmonary
disease
copd
genetic
mitochondrial
diseases
information
please
visit
follow
us
twitter
vtvtherapeutics
statements
release
contains
statements
involve
risks
uncertainties
statements
identified
use
terminology
including
terms
anticipate
believe
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
case
negative
various
comparable
terminology
statements
statements
historical
facts
contained
release
including
statements
regarding
timing
clinical
trials
strategy
future
operations
future
financial
position
future
revenue
projected
costs
prospects
plans
objectives
management
expected
market
growth
statements
statements
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
important
factors
could
cause
results
vary
expectations
include
described
heading
risk
factors
annual
report
form
filings
sec
statements
reflect
views
respect
future
events
date
release
based
assumptions
subject
risks
uncertainties
given
uncertainties
place
undue
reliance
statements
statements
represent
estimates
assumptions
date
release
except
required
law
undertake
obligation
update
review
publicly
statements
whether
result
new
information
future
events
otherwise
date
release
anticipate
subsequent
events
developments
cause
views
change
statements
reflect
potential
impact
future
acquisitions
merger
dispositions
joint
ventures
investments
may
undertake
qualify
statements
cautionary
statements
contact
investors
corey
davis
lifesci
advisors
cdavis
